

1 **Full Title**

2 Sex Differences in Management, Time to Intervention, and In-Hospital Mortality of Acute
3 Myocardial Infarction and Non-Myocardial Infarction Related Cardiogenic Shock

4
5 **Authors**

6 Anushka Desai, BS¹; Rohan Rani, BS¹; Anum Minhas, MD MHS²; Faisal Rahman BM BCh²

- 7
8 1. Georgetown University School of Medicine
9 2. Division of Cardiology, Johns Hopkins University School of Medicine, Baltimore,
10 Maryland, USA.

11
12 **Short Title**

13 Sex Differences in Cardiogenic Shock

14
15 **Corresponding Author Information**

16 Anushka Desai

17 ad1551@georgetown.edu

18 3603 T Street NW Washington D.C., 20007

19
20 **Total Word Count – 2,218**

21
22 **Acknowledgements**

23 None

24
25 **Sources of Funding**

26 Dr. Minhas is supported by NIH/NHLBI K23HL171886.

27
28 **Disclosures**

29 None

30
31
32
33
34
35
36
37
38
39
40

41 **Abstract**

42 Background

43 Limited data are available on sex differences in the time to treatment of cardiogenic shock (CS)
44 with and without acute myocardial infarction (AMI).

45

46 Methods

47 For this retrospective cohort study, we used nationally representative hospital survey data from
48 the National Inpatient Sample (years 2016-2021) to assess sex differences in interventions, time
49 to treatment (within versus after 24 hours of admission), and in-hospital mortality for AMI-CS
50 and non-AMI-CS, adjusting for age, race, income, insurance, comorbidities, and prior cardiac
51 interventions.

52

53 Results

54 We identified 1,052,360 weighted CS hospitalizations (60% non-AMI-CS; 40% AMI-CS).
55 Women with CS had significantly lower rates of all interventions. For AMI-CS, women had a
56 higher likelihood of in-hospital mortality after: revascularization (adjusted odds ratio (aOR) 1.15
57 [95% CI 1.09-1.22]), mechanical circulatory support (MCS) (1.15 [1.08-1.22]), right heart
58 catheterization (RHC) (1.10 [1.02-1.19]) (all $p < 0.001$). Similar trends were found for the non-
59 AMI-CS group. Women with AMI-CS were less likely to receive early (within 24 hours of
60 admission) revascularization (0.93 [0.89-0.96]), MCS (0.76 [0.73-0.80]), or RHC (0.89 [0.84-
61 0.95]) than men; women with non-AMI-CS were less likely to receive early revascularization
62 (0.78 [0.73-0.84]), IABP (0.85 [0.78-0.94]), pLVAD (0.88 [0.77-0.99]) or RHC (0.83 [0.79-
63 0.88]) than men (all $p < 0.001$). For both types of CS, in-hospital mortality was not significantly
64 different between men and women receiving early ECMO, pLVAD, or PCI.

65

66 Conclusions

67 Sex disparities in the frequency of treatment of CS persist on a national scale, with women being
68 more likely to die following treatment and less likely to receive early treatment. However, when
69 comparing patients who received early treatment, in-hospital mortality does not differ
70 significantly when men and women are treated equally within 24 hours of admission. Early
71 intervention if clinically indicated could mitigate sex-based differences in CS outcomes and
72 should be made a priority in the management of CS.

73

74

75

76

77

78

79

80

81 Clinical Perspective

82 What is new?

- 83 ● Women have increased in-hospital mortality with cardiogenic shock and have lower odds
84 of early intervention (within 24 hours of admission) compared to men.
85 ● When men and women with cardiogenic shock are treated equally in terms of early
86 intervention within 24 hours of admission, sex differences in in-hospital mortality
87 disappear.

88

89 What are the clinical implications?

- 90 ● Sex-based disparities are present in the utilization of treatment and time to intervention
91 for patients with cardiogenic shock.
92 ● Early recognition and intervention for cardiogenic shock among women should be
93 considered to improve clinical outcomes.

94

95

96 **Abbreviations**

97 CS – Cardiogenic Shock

98 AKI – Acute Kidney Injury

99 AMI – Acute Myocardial Infarction

100 MCS – Mechanical Circulatory Support

101 RHC – Right Heart Catheterization

102 HCUP – Healthcare Cost and Utilization Project

103 NIS – National Inpatient Sample

104 PCI – Percutaneous Intervention

105 CABG – Coronary Artery Bypass Graft

106 IABP – Intra-Aortic Balloon Pump

107 pLVAD – Percutaneous Left Ventricular Assist Device

108 LVAD – Left Ventricular Assist Device

109 ECMO – Extracorporeal Membrane Oxygenation

110 aOR – Adjusted Odds Ratio

111

112

113

114

115

116

117

118

119

120

121 **Introduction**

122 Cardiogenic shock (CS) is defined as a state of decreased circulation causing hypoxia and end-
123 organ hypoperfusion. It is frequently precipitated by acute myocardial infarction (AMI).¹ Despite
124 advancements in medical interventions over the past 20 years, CS remains associated with high
125 mortality ranging between 30-50%.²⁻⁵ There exist marked sex disparities in mortality associated
126 with CS in the United States.⁶⁻⁸ Current literature suggests insufficient recognition of symptoms
127 in women, faltering guideline-directed medical therapy during the first 24 hours, and inadequate
128 utilization of mechanical circulatory support (MCS) devices as underlying reasons for the
129 observed mortality difference.⁹

130
131 In all patients, rapid deterioration following CS necessitates timely intervention to improve
132 clinical outcomes.^{10,11} Recently, the DanGer Shock trial has driven the point of early aggressive
133 treatment of AMI-CS, finding that prompt routine use of percutaneous left ventricular assist
134 devices (pLVAD) decreases the risk of all-cause mortality.¹² This is especially pertinent when
135 considering a recent cohort study that found women to be less likely to receive pLVAD when
136 hospitalized for CS.¹³ Given that earlier intervention can result in improved clinical outcomes,
137 we aimed to investigate whether differences in timely intervention were associated with higher
138 mortality among women compared to men.

139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160

161 **Methods**

162 Study Data

163 Data was obtained from the Healthcare Cost and Utilization Project (HCUP) National Inpatient
164 Sample (NIS) database, which is sponsored by the Agency of Healthcare Research and Quality.
165 The NIS is the largest publicly available all-payer administrative database in the United States. It
166 contains hospitalization data from a stratified 20% sample of over 1,000 hospitals across the
167 nation participating in the HCUP, and, when weighted, can be used to estimate nationwide trends
168 and incidence.

169 170 Study Population & Outcomes

171 The database was queried for adult patients (≥ 18 years) admitted with CS from 2016 to 2021,
172 using the International Classification of Disease 10th Revision Clinical Modification Codes of
173 R57.0. We categorized these hospitalizations by the presence of AMI on admission into two
174 cohorts: non-AMI CS and AMI-CS. Hospitalizations missing mortality or sex data were
175 excluded. Study flowchart is included in **Figure S1**.

176
177 Baseline demographics, comorbidities, and prior interventions were identified with ICD-10-CM
178 codes. These characteristics included census-defined age group, race/ethnicity, quartile of
179 median household income, insurance, hospital type, hospital teaching status, obesity,
180 dyslipidemia, diabetes mellitus, hypertension, tobacco use, peripheral vascular disease, chronic
181 heart failure, chronic kidney disease, chronic liver disease, valvular heart disease, coronary artery
182 disease, stroke, prior percutaneous intervention (PCI), and prior coronary artery bypass graft
183 (CABG).

184
185 The procedural outcomes analyzed were revascularization (Percutaneous Coronary Intervention
186 [PCI] and Coronary Artery Bypass Graft [CABG]), MCS (Intra-aortic Balloon Pump [IABP],
187 Percutaneous Left Ventricular Assist Device [pLVAD], Extracorporeal Membrane Oxygenation
188 [ECMO]), RHC, and advanced heart failure therapies (LVAD and heart transplant). The clinical
189 outcomes studied included in-hospital mortality, use of invasive mechanical ventilation, major
190 bleeding, acute kidney injury, and stroke. **Table S1** includes a complete list of all ICD-10
191 diagnosis and procedure codes used.

192 193 Statistical Analysis

194 All data represent weighted national estimates, which were done using HOSP_NIS as a
195 clustering variable and NIS_STRATUM to account for different strata, as recommended by the
196 AHRQ methods.¹⁴ Differences in baseline data, procedural outcomes, and clinical outcomes
197 between the type of CS and sex were compared using Pearson's χ^2 test for categorical variables
198 and the Mann-Whitney test for continuous variables.

199

200 Multivariable logistic regressions that accounted for survey weighting were used to assess sex
201 differences in use of intervention at any point during hospitalization, early treatment (within 24
202 hours of admission), and adverse clinical outcomes for both AMI and non-AMI CS, adjusting for
203 all baseline demographics, comorbidities, and prior interventions. Further subgroup analyses
204 were performed to assess sex differences in in-hospital mortality associated with receiving early
205 versus late intervention.

206
207 Statistical significance was defined with a type I error of < 0.05 . All analyses were performed
208 using STATA Statistical Software version 18.0.

209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239

240 **Results**

241 Baseline Characteristics

242 Our study included 1,052,360 weighted hospitalizations with CS between 2016 and 2021. As
243 seen in **Table 1**, both non-AMI-CS and AMI-CS had a higher incidence in men compared to
244 women (non-AMI-CS 61.8% vs 38.1%; AMI-CS 63.6% vs 36.3%; $p<0.001$). Women were more
245 likely to be older with CS. Women with CS, compared to men, had higher frequencies of obesity,
246 valvular heart disease, and stroke, and lower frequencies of coronary artery disease and prior PCI
247 or CABG ($p<0.001$).

248

249 Procedural and Clinical Outcomes

250 For both types of CS, women had significantly lower frequencies of almost every type of
251 intervention compared to men ($p<0.001$), the only exception being heart transplant for AMI-CS
252 (**Table 2**). Women had higher frequencies of in-hospital mortality, use of mechanical ventilation,
253 and stroke during hospitalization, and lower frequencies of major bleeding events and acute
254 kidney injury compared to men. Hospital length of stay and total charges were significantly
255 lower for women than men. These trends were observed after adjusting for baseline
256 characteristics and comorbidities as well (**Tables S2-3**).

257

258 Outcomes after Intervention for AMI-CS

259 Women with AMI-CS undergoing revascularization had higher mortality (aOR: 1.15; 95% CI:
260 1.09-1.22; $p<0.001$), were more likely to require mechanical ventilation (aOR: 1.07; 95% CI:
261 1.02-1.12; $p=0.003$), and have a stroke (aOR: 1.62; 95% CI: 1.12-2.35; $p<0.001$) during their
262 hospitalization compared to men (**Table 3**). When MCS was utilized, women were more likely to
263 have higher mortality (adjusted odds ratio (aOR): 1.15; 95% CI: 1.08-1.22; $p<0.001$), be placed
264 on mechanical ventilation (aOR: 1.12; 95% CI: 1.06-1.19; $p<0.001$), or have a major bleeding
265 event (aOR: 1.08; 95% CI: 1.01-1.15; $p=0.01$) during their hospitalization than men. After RHC,
266 women were more likely to die (aOR: 1.10; 95% CI: 1.02-1.19; $p<0.001$) or be placed on
267 mechanical ventilation (aOR: 1.12; 95% CI: 1.04-1.21; $p=0.002$) during their hospitalization than
268 men. No significant differences in adverse clinical outcomes between men and women receiving
269 advanced heart failure therapy were noted.

270

271 Outcomes after Intervention for non-AMI-CS

272 Following revascularization, women with non-AMI-CS were more likely to die (aOR: 1.38; 95%
273 CI: 1.23-1.56; $p<0.001$) and be placed on mechanical ventilation (aOR: 1.11; 95% CI: 1.00-1.24;
274 $p=0.050$) during their hospitalization than men (**Table 4**). Women receiving MCS were more
275 likely to die (aOR: 1.31; 95% CI: 1.21-1.43; $p<0.001$), be placed on mechanical ventilation
276 (aOR: 1.28; 95% CI: 1.18-1.40; $p<0.001$), or have a major bleeding event (aOR: 1.10; 95% CI:
277 1.02-1.18; $p=0.012$) during their hospitalization than men. The same was true after RHC for in-
278 hospital mortality (aOR: 1.32; 95% CI: 1.22-1.43; $p<0.001$) and mechanical ventilation usage

279 (aOR: 1.27; 95% CI: 1.17-1.36; $p < 0.001$). No significant differences in adverse clinical
280 outcomes between men and women receiving advanced heart failure therapy were noted.

281

282 Incidence and Mortality Following Early Intervention

283 For both types of shock, women had a lower frequency of receiving CABG, IABP, pLVAD, and
284 RHC within 24 hours of admission compared to men (**Figure 1**). Women with AMI-CS
285 additionally had lower frequencies of undergoing placement on ECMO and PCI within 24 hours.
286 This was similarly reflected after adjusting for covariates, with women with AMI-CS being less
287 likely to receive any type of revascularization, MCS, or RHC than men, and women with non-
288 AMI-CS being less likely to receive any type of revascularization, IABP, pLVAD, RHC, or
289 LVAD than men (**Figure 2**). In-hospital mortality did not change significantly between men and
290 women with AMI-CS undergoing early revascularization, pLVAD, ECMO, or RHC (**Figure 3**).
291 For those with non-AMI-CS, in-hospital mortality did not change significantly when treated
292 early with PCI, pLVAD, ECMO, or RHC (**Figure 3**). For AMI-CS, women receiving early
293 interventions of any revascularization or within 24 hours were far less likely to die during their
294 hospitalization than women who received intervention after 24 hours or not at all; meanwhile, for
295 non-AMI-CS, this was the case for women receiving early CABG, IABP, or RHC (**Table 5**).

296

297

298

299

300

301

302

303

304

305

306

307

308

309

310

311

312

313

314

315

316

317

318

319 Discussion

320 To our knowledge, this study is the first to examine sex differences in management and
321 outcomes of patients with AMI-CS and non-AMI-CS utilizing time to intervention. We found
322 that (1) women with either type of CS are less likely to undergo interventions during
323 hospitalization than men; (2) even after receiving intervention, in-hospital mortality, mechanical
324 ventilation, and major bleeding are more likely to occur in women with CS than men; (3) among
325 patients undergoing intervention, women are less likely to have an intervention performed within
326 24 hours of admission; (4) and with early intervention, there was no difference in mortality
327 among women and men.

328
329 Previous studies have demonstrated that women are less likely to receive MCS therapies in CS
330 and experience a 10% higher mortality risk.¹¹ Not only did we confirm these findings, but we
331 also found that women had significantly lower frequencies of nearly all types of interventions
332 compared to men and were less likely to receive these interventions early. This was associated
333 with higher frequencies of in-hospital mortality, invasive mechanical ventilation, and stroke
334 during hospitalization. Prior analyses of NIS data from 2006 to 2015 found that, for AMI-CS,
335 women were more likely to die during their hospitalization than men (aOR 1.11, 95% CI: 1.06-
336 1.16 $p < 0.001$).¹⁵ Despite significant recognition of sex disparities in management and mortality
337 rates of many conditions, our analysis shows that the situation has yet to improve significantly in
338 the subsequent decade for CS.

339
340 The results of this study suggest that ongoing sex disparities in mortality and outcomes of CS
341 may be related to time to intervention. When women and men are similarly treated with early
342 intervention for CS, outcomes are comparable. Additionally, women with CS undergoing any
343 revascularization, IABP, or RHC within 24 hours of admission were far less likely to die during
344 their hospitalization than women who received intervention after 24 hours or not at all. Both of
345 these findings point to late intervention as a plausible explanation for the observed outcome
346 differences and demonstrate the tangible impact of timely intervention in narrowing the sex gap
347 in clinical outcomes for CS.

348
349 Research has extensively explored the elevated mortality in women with CS, especially within
350 the context of AMI. One hypothesis posits that women in low-output states are less likely to be
351 recognized by providers as experiencing CS. This is supported by studies on sex-based
352 differences in time to treatment for AMI, showing delays at every stage of care (from symptom
353 onset to EMS call, EMS to hospital admission, and hospital admission to reperfusion therapy).¹⁶
354 Early intervention has been shown to be crucial in the treatment of CS, leading to better post-
355 procedure outcomes and lower rates of in- and out-hospital mortality.^{17,18} Reasons for this
356 include improved perfusion resulting in the prevention of irreversible ischemic damage and
357 pathologic cardiac remodeling.

358

359 Clinically, improving recognition of low-output states in women can lead to decreased time to
360 treatment for CS. When looking at the temporal trends of women undergoing AMI, female sex
361 has been associated with a greater time to reperfusion even when adjusting for all baseline
362 characteristics and types of reperfusion therapy used.^{19,20} It is equally important to note that
363 when performing a clinical assessment of suspected AMI, symptom presentation varies not only
364 by sex, but also by race; for example, Black women are more likely to present with GI distress,
365 while White women are more likely to present with typical chest pain.²¹ Noting these differences
366 in symptom presentation is significant, as an atypical presentation with acute-onset GI distress
367 can modify the differential to include a diagnosis of GERD or peptic ulcer disease, which would
368 subsequently contribute to poorer outcomes, especially in Black women.

369

370 **Limitations**

371 There were a few limitations that were present in this study. The diagnosis of CS was based on
372 ICD-CM codes used for billing purposes, which are susceptible to erroneous coding. However,
373 previous studies comparing ICD diagnosis of CS to physician adjudication in hospital systems
374 that validate these codes have demonstrated that ICD-CM codes are reliably coded and can
375 accurately predict mortality in the context of MI and CS.^{22,23} Also, the NIS database recorded
376 time in units of days as opposed to hours, so more exact timing information was not available.
377 Data included information on hospitalizations as opposed to patient-level data, which opens the
378 possibility of repeat patients in the sample. Additionally, specific data such as vital signs,
379 laboratory, and echocardiogram data were not available. Finally, there was a lack of information
380 on post-discharge outcomes, which could have provided further insight into post-intervention
381 results from the management of CS.

382

383 **Conclusions**

384 Our study found that, despite stark differences in access to early intervention for CS between
385 men and women, in-hospital mortality did not differ significantly between sexes when treated
386 equally within 24 hours of admission. Early intervention plays a role in mitigating sex-based
387 differences in CS outcomes and should be prioritized in the management of CS. Future research
388 should focus on recognizing the atypical presentations of CS in women, identifying signs and
389 symptoms earlier in the disease course, and validating our findings in other cohorts.

390

391

392

393

394

395

396

397

398

399 References

- 400 1. Daoulah A, Alshehri M, Panduranga P, et al. Clinical outcomes of patients with
401 cardiogenic shock complicating acute myocardial infarction: The Gulf-Cardiogenic
402 Shock (G-CS) Registry. *Shock*. 2024 Aug 12. doi:10.1097/SHK.0000000000002433.
403 Epub ahead of print. PMID: 39158570.
- 404 2. Aissaoui N, Puymirat E, Delmas C, et al. Trends in cardiogenic shock complicating acute
405 myocardial infarction. *Eur J Heart Fail*. 2020;22(4):664-672. doi:10.1002/ejhf.1750.
- 406 3. Bertaina M, Morici N, Frea S, et al. Differences between cardiogenic shock related to
407 acute decompensated heart failure and acute myocardial infarction. *ESC Heart Fail*.
408 2023;10(6):3472-3482. doi:10.1002/ehf2.14510.
- 409 4. Chioncel O, Parissis J, Mebazaa A, et al. Epidemiology, pathophysiology and
410 contemporary management of cardiogenic shock - a position statement from the Heart
411 Failure Association of the European Society of Cardiology. *Eur J Heart Fail*.
412 2020;22(8):1315-1341. doi:10.1002/ejhf.1922.
- 413 5. Luna P, Kim LK, Yeo I, et al. Sex disparities in the management, outcomes, and transfer
414 of patients hospitalized for cardiogenic shock. *J Soc Cardiovasc Angiogr Interv*.
415 2023;3(3Part A):101212. doi:10.1016/j.jscv.2023.101212. PMID: 39131782; PMCID:
416 PMC11307867.
- 417 6. Takla A, Mostafa MR, Eid MM, et al. Sex difference in outcomes and management of
418 cardiogenic shock: A systematic review and meta-analysis. *Curr Probl Cardiol*.
419 2024;49(11):102777. doi:10.1016/j.cpcardiol.2024.102777. Epub ahead of print. PMID:
420 39103132.
- 421 7. Abdallah N, Mohamoud A, Almasri T, et al. Relationships between sex and in-hospital
422 outcomes of patients with acute cardiogenic shock receiving mechanical circulatory
423 support. *Cardiovasc Revasc Med*. 2024 Jul 20:S1553-8389(24)00594-3.
424 doi:10.1016/j.carrev.2024.07.017. Epub ahead of print. PMID: 39054172.
- 425 8. Elgendy IY, Wegermann ZK, Li S, et al. Sex differences in management and outcomes of
426 acute myocardial infarction patients presenting with cardiogenic shock. *JACC Cardiovasc*
427 *Interv*. 2022;15(6):642-652. doi:10.1016/j.jcin.2021.12.033. PMID: 35331456.
- 428 9. Suzuki S, Ito K, Teraoka N, et al. Treatment time limit for successful weaning from
429 veno-arterial extracorporeal membrane oxygenation in cardiogenic shock. *ESC Heart*
430 *Fail*. 2024 Jul 11. doi:10.1002/ehf2.14931. Epub ahead of print. PMID: 38992944.
- 431 10. Shirakabe A, Matsushita M, Shibata Y, et al. Organ dysfunction, injury, and failure in
432 cardiogenic shock. *J Intensive Care*. 2023;11(1):26. doi:10.1186/s40560-023-00676-1.
433 PMID: 37386552; PMCID: PMC10308671.
- 434 11. Fisher T, Hill N, Kalakoutas A, et al. Sex differences in treatments and outcomes of
435 patients with cardiogenic shock: a systematic review and epidemiological meta-analysis.
436 *Crit Care*. 2024;28(1):192. doi:10.1186/s13054-024-04973-5.
- 437 12. Møller JE, Engstrøm T, Jensen LO, et al. Microaxial flow pump or standard care in
438 infarct-related cardiogenic shock. *N Engl J Med*. 2024;390(15):1382-1393.
- 439 13. Yan I, et al. Sex differences in patients with cardiogenic shock. *ESC Heart Fail*.
440 2021;8(3):1775-1783. doi:10.1002/ehf2.13303.
- 441 14. HCUP National Readmission Database (NRD). Healthcare Cost and Utilization Project
442 (HCUP). Agency for Healthcare Research and Quality. Accessed October 09, 2021.
443 <https://www.hcup-us.ahrq.gov/nrdoverview.jsp>
- 444 15. Ya'qoub L, Lemor A, Dabbagh M, et al. Racial, ethnic, and sex disparities in patients

- 445 with STEMI and cardiogenic shock. *J Am Coll Cardiol Interv.* 2021;14(6):653-660.
446 doi:10.1016/j.jcin.2021.01.003.
- 447 16. Stehli J, Dinh D, Dagan M, et al. Sex differences in prehospital delays in patients with
448 ST-segment–elevation myocardial infarction undergoing percutaneous coronary
449 intervention. *JAHA.* 2021;10(13):e019938. doi:10.1161/JAHA.120.019938.
- 450 17. Azazy A, Farid WA, Ibrahim WA, El Shafey WEH. Survival benefit of IABP in pre-
451 versus post-primary percutaneous coronary intervention in patients with cardiogenic
452 shock. *Egypt Heart J.* 2024;76(1):99. doi:10.1186/s43044-024-00527-w. PMID:
453 39107654; PMCID: PMC11303647.
- 454 18. Brodie BR, Stuckey TD, Muncy DB, et al. Importance of time-to-reperfusion in patients
455 with acute myocardial infarction with and without cardiogenic shock treated with primary
456 percutaneous coronary intervention. *Am Heart J.* 2003;145(4):708-715.
457 doi:10.1067/mhj.2003.9. PMID: 12679769.
- 458 19. Kaul P, et al. Temporal trends in patient and treatment delay among men and women
459 presenting with ST-elevation myocardial infarction. *Am Heart J.* 2011;161(1):91-97.
460 doi:10.1016/j.ahj.2010.09.016.
- 461 20. Lansky AJ, et al. Gender differences in outcomes after primary angioplasty versus
462 primary stenting with and without abciximab for acute myocardial infarction: results of
463 the Controlled Abciximab and Device Investigation to Lower Late Angioplasty
464 Complications (CADILLAC) trial. *Circulation.* 2005;111(13):1611-1618.
465 doi:10.1161/01.CIR.0000160362.55803.40.
- 466 21. Eastwood J, et al. Anginal symptoms, coronary artery disease, and adverse outcomes in
467 Black and White women: the NHLBI-sponsored Women’s Ischemia Syndrome
468 Evaluation (WISE) study. *J Womens Health.* 2013;22(9):724-732.
469 doi:10.1089/jwh.2012.4031.
- 470 22. Lambert L, et al. Evaluation of care and surveillance of cardiovascular disease: can we
471 trust medico-administrative hospital data? *Can J Cardiol.* 2012;28(2):162-168.
472 doi:10.1016/j.cjca.2011.10.005.
- 473 23. Lauridsen MD, Gammelager H, Schmidt M, et al. Positive predictive value of
474 International Classification of Diseases, 10th revision, diagnosis codes for cardiogenic,
475 hypovolemic, and septic shock in the Danish National Patient Registry. *BMC Med Res*
476 *Methodol.* 2015;15:23. doi:10.1186/s12874-015-0013-2.

Table 1. Baseline characteristics of patients stratified by CS type and sex (weighted).

	Non-AMI-CS 631,655 (60.0)			AMI-CS 420,705 (40.0)		
	Male 390,505 (61.8)	Female 241,150 (38.2)	p-value <0.001	Male 267,810 (63.7)	Female 152,895 (36.3)	p-value <0.001
Demographics						
Age Group						
18-44	39,125 (10.0)	24,930 (10.3)	<0.001	11,845 (4.4)	5,795 (3.8)	<0.001
45-64	141,780 (36.3)	72,050 (29.9)		96,105 (35.9)	41,370 (27.0)	
65-84	182,565 (46.8)	116,715 (47.4)		137,165 (51.2)	82,500 (53.9)	
85+	27,035 (6.9)	27,455 (11.4)		22,695 (8.5)	23,230 (15.2)	
Race/Ethnicity						
White	246,835 (65.6)	147,395 (63.4)	<0.001	183,020 (71.4)	103,525 (70.4)	<0.001
Black	69,525 (18.5)	50,275 (21.6)		25,015 (9.7)	19,365 (13.2)	
Hispanic	34,005 (9.0)	19,785 (8.5)		25,700 (10.0)	13,000 (8.8)	
Asian	11,365 (3.0)	7,065 (3.0)		10,675 (4.2)	5,080 (3.5)	
Native American	2,570 (0.7)	1,505 (0.6)		1,715 (0.7)	1,170 (0.8)	
Other	11,785 (3.1)	6,585 (2.8)		10,215 (4.0)	4,875 (3.3)	
Quartile of Median Household Income by Zipcode (Percentile)						
<25 th	116,585 (30.5)	76,505 (32.3)	<0.001	76,210 (29.0)	47,690 (31.7)	<0.001
26 th – 50 th	99,445 (26.0)	61,950 (26.1)		70,715 (27.0)	40,985 (27.3)	
51 th – 75 th	90,070 (23.6)	54,665 (23.0)		63,025 (24.0)	34,420 (22.9)	
76 th – 100 th	76,250 (19.9)	44,125 (18.6)		52,075 (19.9)	27,325 (18.2)	
Insurance						
Medicare	223,675 (57.4)	155,185 (64.4)	<0.001	154,770 (57.9)	106,735 (69.9)	<0.001
Medicaid	55,630 (14.3)	31,890 (13.2)		28,365 (10.6)	14,545 (9.5)	
Private	82,505 (21.2)	43,480 (18.0)		60,715 (22.7)	24,240 (15.9)	
Self-Pay	13,670	5,905		12,610	4,630	

	(3.5)	(2.5)		(4.7)	(3.0)	
No Charge	695 (0.2)	365 (0.2)		810 (0.3)	305 (0.2)	
Other	13,805 (3.5)	4,040 (1.7)		10,105 (3.8)	2,275 (1.5)	
Hospital Type						
Government	47,950 (12.3)	28,495 (11.8)	0.013	26,165 (9.8)	14,035 (9.2)	<0.001
Private, Non-Profit	301,035 (77.0)	185,990 (77.1)		200,540 (74.9)	116,325 (76.0)	
Private, For-Profit	41,520 (10.6)	26,665 (11.0)		41,105 (15.4)	22,535 (14.7)	
Hospital Teaching Status						
Rural	13,175 (3.4)	9,290 (3.9)	<0.001	12,140 (4.5)	8,195 (5.4)	<0.001
Urban, Non-Teaching	52,265 (13.4)	34,915 (14.5)		46,230 (17.3)	26,635 (17.4)	
Urban, Teaching	325,065 (83.2)	196,945 (81.7)		209,440 (78.2)	118,065 (77.2)	
Comorbidities & Prior Interventions						
Obesity	68,960 (17.7)	49,945 (20.7)	<0.001	42,130 (15.7)	27,410 (17.9)	<0.001
Dyslipidemia	162,685 (41.7)	91,920 (38.1)	<0.001	136,680 (51.0)	75,520 (49.4)	<0.001
Diabetes Mellitus	149,720 (38.3)	88,565 (36.7)	<0.001	112,160 (41.9)	67,555 (44.2)	<0.001
Chronic Hypertension	296,000 (75.8)	175,060 (72.6)	<0.001	199,995 (74.7)	117,175 (76.6)	<0.001
Tobacco Use	48,555 (12.4)	22,225 (9.2)	<0.001	46,430 (17.3)	21,345 (14.0)	<0.001
Peripheral Vascular Disease	21,535 (5.5)	11,165 (4.6)	<0.001	19,510 (7.3)	11,575 (7.6)	0.137
Chronic Heart Failure	156,605 (40.1)	96,585 (40.0)	0.859	95,455 (35.6)	57,405 (37.6)	<0.001
Chronic Kidney Disease	175,165 (44.9)	90,745 (37.6)	<0.001	89,720 (33.5)	49,225 (32.2)	<0.001
Chronic Liver Disease	101,045 (25.9)	56,175 (23.3)	<0.001	61,715 (23.0)	31,420 (20.6)	<0.001
Valvular Heart Disease	100,290 (25.7)	69,700 (28.9)	<0.001	46,935 (17.5)	32,640 (21.4)	<0.001
Coronary Artery Disease	195,860 (50.2)	86,305 (35.8)	<0.001	202,640 (75.7)	103,145 (67.5)	<0.001
Stroke	13,035 (3.3)	8,715 (3.6)	0.007	11,500 (4.3)	7,470 (4.9)	<0.001
Prior PCI	38,505 (9.9)	14,760 (6.1)	<0.001	34,094 (12.7)	15,360 (10.0)	<0.001

Prior CABG	39,770 (10.2)	12,175 (5.0)	<0.001	24,925 (9.3)	9,785 (6.4)	<0.001
------------	------------------	-----------------	--------	-----------------	----------------	--------

Results presented as n (%). Comparisons made using Pearson's χ^2 test. Comparisons made using Pearson's χ^2 test for categorical variables and Mann-Whitney test for continuous variables. All analyses are survey weight adjusted. Abbreviations: AMI-CS, acute myocardial infarction cardiogenic shock; PCI, percutaneous coronary intervention; CABG, coronary artery bypass grafting.

Table 2. Frequency of procedural and clinical outcomes stratified by sex and CS type.

	Non-AMI-CS 631,655 (60.02)			AMI-CS 420,705 (39.98)		
	Male 390,505 (61.8)	Female 241,150 (38.2)	p-value <0.001	Male 267,810 (63.7)	Female 152,895 (36.3)	p-value <0.001
Procedural Outcomes						
Revascularization	39,770 (10.2)	15,395 (6.4)	<0.001	140,215 (52.4)	67,770 (44.3)	<0.001
PCI	9,385 (2.4)	4,555 (1.9)	<0.001	104,185 (38.9)	53,160 (34.8)	<0.001
CABG	32,110 (8.2)	11,570 (4.8)	<0.001	47,465 (17.7)	18,735 (12.3)	<0.001
MCS	49,290 (12.6)	21,795 (9.0)	<0.001	96,320 (36.0)	41,710 (27.3)	<0.001
IABP	27,615 (7.1)	11,745 (4.9)	<0.001	65,870 (24.6)	29,565 (19.3)	<0.001
pLVAD	18,655 (4.8)	6,875 (2.5)	<0.001	32,750 (12.2)	13,050 (8.5)	<0.001
ECMO	11,300 (2.9)	6,445 (2.7)	0.026	7,885 (2.9)	2,635 (1.7)	<0.001
RHC	82,485 (21.1)	40,015 (16.6)	<0.001	51,600 (19.3)	25,800 (16.9)	<0.001
Advanced Heart Failure Therapy	17,100 (4.4)	5,590 (2.3)	<0.001	1,580 (0.6)	510 (0.3)	<0.001
LVAD	10,630 (2.7)	3,100 (1.3)	<0.001	1,300 (0.5)	380 (0.3)	<0.001
Heart Transplant	6,595 (1.7)	2,530 (1.0)	<0.001	310 (0.1)	130 (0.1)	0.151
Clinical Outcomes						
In-hospital Mortality	118,205 (30.3)	85,360 (35.4)	<0.001	90,940 (34.0)	58,355 (38.2)	<0.001
Invasive Mechanical Ventilation	106,950 (27.4)	74,690 (31.0)	<0.001	89,655 (33.5)	52,860 (34.6)	0.001
Major Bleeding	81,895 (21.0)	48,495 (20.1)	<0.001	53,865 (20.1)	29,420 (19.2)	0.003
Acute Kidney Injury	265,625 (68.0)	149,005 (61.8)	<0.001	163,645 (61.1)	85,090 (55.7)	<0.001
Acute Kidney Injury	31,800	17,715	<0.001	18,270	8,755	<0.001

Requiring Dialysis	(8.1)	(7.4)		(6.8)	(5.7)	
Stroke	985 (0.3)	1,025 (0.4)	<0.001	645 (0.2)	605 (0.4)	<0.001
Total Hospitalization Cost in USD (mean, standard error)	268,220.4 (4,607.4)	233,424.5 (3,528.7)	<0.001	254,776.1 (2,762.1)	216,624.1 (2,376.2)	<0.001
Length of Stay in days (mean, standard error)	12.65 (0.10)	11.82 (0.10)	<0.001	9.99 (0.06)	9.32 (0.07)	<0.001

Results presented as (%), unless otherwise noted. Comparisons made using Pearson's χ^2 test for categorical variables. All analyses are survey weight adjusted.

Abbreviations: AMI-CS, acute myocardial infarction cardiogenic shock; PCI, percutaneous coronary intervention; CABG, coronary artery bypass grafting; MCS, mechanical support device; IABP, intra-aortic balloon pump; pLVAD, percutaneous left ventricular support device; ECMO, extracorporeal membrane oxygenation; RHC, right heart catheterization; LVAD, left ventricular assist device.

Table 3. Odds ratios of clinical outcomes in women versus men with AMI-CS based on first intervention type received.

Outcomes in Women compared to Men	Unadjusted Odds Ratio	p-value	Model 1 (Only Demographics) Odds Ratio	p-value	Model 2 (All Baseline Characteristics) Odds Ratio	p-value
Revascularization						
In-hospital Mortality	1.23 (1.18-1.29)	<0.001	1.13 (1.08-1.19)	<0.001	1.15 (1.09-1.22)	<0.001
IMV	1.06 (1.01-1.10)	0.011	1.06 (1.01-1.10)	0.013	1.07 (1.02-1.12)	0.003
Major Bleeding	1.02 (0.97-1.07)	0.322	1.02 (0.98-1.08)	0.245	0.98 (0.94-1.04)	0.689
AKI	0.79 (0.76-0.83)	<0.001	0.73 (0.70-0.76)	<0.001	0.71 (0.67-0.74)	<0.001
AKI Requiring Dialysis	0.89 (0.81-0.98)	0.021	0.87 (0.79-0.97)	0.013	0.86 (0.77-0.96)	0.007
Stroke	1.78 (1.25-3.52)	0.001	1.67 (1.16-2.40)	0.006	1.62 (1.12-2.35)	0.010
MCS						
In-hospital Mortality	1.19 (1.13-1.26)	<0.001	1.12 (1.06-1.19)	<0.001	1.15 (1.08-1.22)	<0.001
IMV	1.11 (1.05-1.17)	<0.001	1.10 (1.04-1.17)	0.001	1.12 (1.06-1.19)	<0.001
Major Bleeding	1.10 (1.04-1.17)	0.001	1.11 (1.04-1.18)	0.001	1.08 (1.01-1.15)	0.015
AKI	0.78 (0.74-0.82)	<0.001	0.74 (0.70-0.78)	<0.001	0.72 (0.68-0.76)	<0.001
AKI Requiring Dialysis	0.85 (0.77-0.94)	0.003	0.84 (0.76-0.94)	0.002	0.83 (0.74-0.93)	0.002
Stroke	1.52 (0.92-2.50)	0.104	1.46 (0.87-2.45)	0.153	1.33 (0.77-2.29)	0.309
RHC						
In-hospital Mortality	1.12 (1.04-1.20)	0.001	1.06 (0.99-1.15)	0.085	1.10 (1.02-1.19)	0.008
IMV	1.09 (1.02-1.18)	0.008	1.11 (1.04-1.20)	0.003	1.12 (1.04-1.21)	0.002
Major Bleeding	1.03 (0.96-1.11)	0.357	1.05 (0.98-1.14)	0.158	1.03 (0.95-1.12)	0.378
AKI	0.71 (0.66-0.76)	<0.001	0.68 (0.63-0.73)	<0.001	0.69 (0.64-0.75)	<0.001
AKI Requiring Dialysis	0.76 (0.67-0.86)	<0.001	0.73 (0.64-0.83)	<0.001	0.76 (0.66-0.87)	<0.001
Stroke	1.12 (0.63-1.99)	0.687	1.06 (0.59-1.90)	0.837	0.96 (0.52-1.77)	0.901
Advanced Heart Failure Therapy						
In-hospital Mortality	1.13 (0.58-2.20)	0.705	1.12 (0.48-2.59)	0.790	1.37 (0.54-3.50)	0.503
IMV	1.17 (0.63-2.15)	0.618	1.11 (0.55-2.25)	0.751	1.16 (0.58-2.34)	0.667
Major Bleeding	1.26 (0.77-2.08)	0.352	1.64 (0.91-2.96)	0.096	1.59 (0.87-2.89)	0.126

AKI	0.77 (0.44-1.35)	0.363	0.85 (0.48-1.51)	0.579	0.81 (0.41-1.58)	0.525
AKI Requiring Dialysis	1.21 (0.57-2.58)	0.616	1.53 (0.61-3.87)	0.360	1.76 (0.58-5.33)	0.317
Stroke	1.55 (0.14-17.6)	0.721	9.66 (0.52-179)	0.124	N/A	N/A

All analyses involve multivariate logistic regression and are survey weight adjusted. Model 1 includes adjustment with year of NIS data, age group, race, household income quartile, insurance status, hospital type and teaching status. Model 2 includes adjustment with all model 1 covariates as well as past medical history of diabetes mellitus, hypertension, dyslipidemia, tobacco use, obesity, chronic kidney disease, liver disease, peripheral vascular disease, coronary artery disease, chronic heart failure, valvular heart disease, stroke, prior PCI, and prior CABG. Abbreviations: AMI-CS, acute myocardial infarction cardiogenic shock; MCS, mechanical support device; RHC, right heart catheterization; IMV, invasive mechanical ventilation; AKI, acute kidney injury.

Table 4. Odds ratios of clinical outcomes in women versus men with Non-AMI-CS based on first intervention type received.

Outcomes in Women compared to Men	Unadjusted Odds Ratio	p-value	Model 1 (Only Demographics) Odds Ratio	p-value	Model 2 (All Baseline Characteristics) Odds Ratio	p-value
Revascularization						
In-hospital Mortality	1.43 (1.28-1.59)	<0.001	1.37 (1.22-1.54)	<0.001	1.38 (1.23-1.56)	<0.001
IMV	1.11 (1.00-1.23)	0.033	1.10 (0.99-1.23)	0.060	1.11 (1.00-1.24)	0.050
Major Bleeding	1.11 (1.02-1.21)	0.011	1.16 (1.06-1.27)	0.001	1.09 (0.99-1.19)	0.068
AKI	0.86 (0.79-0.94)	0.001	0.86 (0.78-0.94)	0.001	0.82 (0.74-0.90)	<0.001
AKI Requiring Dialysis	1.01 (0.85-1.21)	0.856	0.99 (0.82-1.19)	0.924	0.95 (0.78-1.16)	0.638
Stroke	1.29 (0.67-2.48)	0.439	1.42 (0.71-2.86)	0.318	1.32 (0.66-2.65)	0.423
MCS						
In-hospital Mortality	1.30 (1.20-1.40)	<0.001	1.30 (1.20-1.42)	<0.001	1.31 (1.21-1.43)	<0.001
IMV	1.27 (1.17-1.37)	<0.001	1.27 (1.17-1.39)	<0.001	1.28 (1.18-1.40)	<0.001
Major Bleeding	1.12 (1.05-1.20)	0.001	1.14 (1.06-1.23)	<0.001	1.10 (1.02-1.18)	0.012
AKI	0.68 (0.63-0.73)	<0.001	0.67 (0.62-0.73)	<0.001	0.66 (0.60-0.73)	<0.001
AKI Requiring Dialysis	0.91 (0.82-1.02)	0.114	0.91 (0.81-1.02)	0.126	0.94 (0.82-1.06)	0.324
Stroke	1.64 (0.96-2.83)	0.070	1.69 (0.96-2.98)	0.068	1.64 (0.93-2.89)	0.089
RHC						
In-hospital Mortality	1.30 (1.21-1.39)	<0.001	1.31 (1.22-1.41)	<0.001	1.32 (1.22-1.43)	<0.001
IMV	1.30 (1.21-1.39)	<0.001	1.31 (1.22-1.41)	<0.001	1.27 (1.17-1.36)	<0.001
Major Bleeding	1.01 (0.95-1.08)	0.609	1.02 (0.96-1.09)	0.427	0.98 (0.91-1.04)	0.507
AKI	0.69 (0.65-0.73)	<0.001	0.68 (0.64-0.72)	<0.001	0.73 (0.68-0.77)	<0.001
AKI Requiring Dialysis	0.95 (0.86-1.04)	0.285	0.95 (0.85-1.04)	0.273	1.00 (0.90-1.11)	0.970
Stroke	1.45 (0.89-2.37)	0.127	1.54 (0.93-2.56)	0.090	1.55 (0.91-2.63)	0.104
Advanced Heart Failure Therapy						
In-hospital Mortality	1.05 (0.81-1.36)	0.671	1.13 (0.86-1.50)	0.361	1.20 (0.88-1.63)	0.242
IMV	1.00 (0.81-1.23)	0.952	0.99 (0.79-1.24)	0.969	1.05 (0.84-1.31)	0.635
Major Bleeding	1.03 (0.88-1.20)	0.665	0.99 (0.84-1.16)	0.906	1.02 (0.87-1.20)	0.768
AKI	0.62 (0.52-0.72)	<0.001	0.61 (0.52-0.71)	<0.001	0.68 (0.57-0.81)	<0.001
AKI Requiring Dialysis	0.79 (0.59-1.05)	0.115	0.76 (0.57-1.03)	0.081	0.79 (0.57-1.09)	0.157
Stroke	1.45 (0.65-3.20)	0.354	1.39 (0.60-3.22)	0.432	1.44 (0.62-3.35)	0.393

All analyses involve multivariate logistic regression and are survey weight adjusted. Model 1 includes adjustment with year of NIS data, age group, race, household income quartile, insurance status, hospital type and teaching

status. Model 2 includes adjustment with all model 1 covariates as well as past medical history of diabetes mellitus, hypertension, dyslipidemia, tobacco use, obesity, chronic kidney disease, liver disease, peripheral vascular disease, coronary artery disease, chronic heart failure, valvular heart disease, stroke, prior PCI, and prior CABG. Abbreviations: AMI-CS, acute myocardial infarction cardiogenic shock; MCS, mechanical support device; RHC, right heart catheterization; IMV, invasive mechanical ventilation; AKI, acute kidney injury.

Table 5. Odds ratios of in-hospital mortality in women receiving early (within 24 hours) versus late or no intervention by CS type.

In-hospital Mortality in Women Receiving Early Intervention compared to Women Not Receiving Early Intervention	Unadjusted Odds Ratio	p-value	Model 1 (Only Demographics) Odds Ratio	p-value	Model 2 (All Baseline Characteristics) Odds Ratio	p-value
AMI-CS						
Revascularization	0.65 (0.61-0.69)	<0.001	0.66 (0.62-0.70)	<0.001	0.77 (0.72-0.82)	<0.001
PCI	0.66 (0.63-0.71)	<0.001	0.68 (0.64-0.72)	<0.001	0.79 (0.74-0.85)	<0.001
CABG	0.63 (0.55-0.73)	<0.001	0.63 (0.55-0.74)	<0.001	0.69 (0.59-0.82)	<0.001
MCS	0.87 (0.82-0.93)	<0.001	0.94 (0.88-1.00)	0.068	1.06 (0.99-1.14)	0.073
IABP	0.69 (0.64-0.75)	<0.001	0.72 (0.67-0.78)	<0.001	0.83 (0.77-0.91)	<0.001
pLVAD	1.50 (1.35-1.68)	<0.001	1.67 (1.49-1.88)	<0.001	1.78 (1.58-2.01)	<0.001
ECMO	1.71 (1.32-2.2)	<0.001	2.38 (1.83-3.10)	<0.001	2.15 (1.62-2.85)	<0.001
RHC	0.87 (0.79-0.96)	0.005	0.90 (0.819-0.99)	0.048	0.979 (0.88-1.08)	0.688
Non-AMI-CS						
Revascularization	0.42 (0.37-0.49)	<0.001	0.42 (0.36-0.49)	<0.001	0.57 (0.49-0.67)	<0.001
PCI	0.76 (0.60-0.95)	0.017	0.70 (0.55-0.88)	0.003	0.87 (0.68-1.12)	0.296
CABG	0.32 (0.27-0.39)	<0.001	0.33 (0.28-0.40)	<0.001	0.46 (0.38-0.56)	<0.001
MCS	0.92 (0.82-1.01)	0.109	0.97 (0.87-1.09)	0.663	1.05 (0.94-1.18)	0.360
IABP	0.64 (0.54-0.74)	<0.001	0.65 (0.55-0.77)	<0.001	0.78 (0.67-0.93)	0.005
pLVAD	1.41 (1.14-1.74)	0.001	1.48 (1.19-1.84)	<0.001	1.56 (1.24-1.96)	<0.001
ECMO	1.31 (1.10-1.57)	0.002	1.52 (1.26-1.82)	<0.001	1.40 (1.15-1.69)	0.001
RHC	0.42 (0.37-0.46)	<0.001	0.45 (0.39-0.50)	<0.001	0.50 (0.44-0.57)	<0.001

All analyses involve multivariate logistic regression and are survey weight adjusted. Model 1 includes adjustment with year of NIS data, age group, race, household income quartile, insurance status, hospital type and teaching status. Model 2 includes adjustment with all model 1 covariates as well as past medical history of diabetes mellitus, hypertension, dyslipidemia, tobacco use, obesity, chronic kidney disease, liver disease, peripheral vascular disease, coronary artery disease, chronic heart failure, valvular heart disease, stroke, prior PCI, and prior CABG. Abbreviations: AMI-CS, acute myocardial infarction cardiogenic shock; PCI, percutaneous coronary intervention; CABG, coronary artery bypass grafting; MCS, mechanical support device; IABP, intra-aortic balloon pump; pLVAD, percutaneous left ventricular support device; ECMO, extracorporeal membrane oxygenation; RHC, right heart catheterization; LVAD, left ventricular assist device.

Figure 1. Frequency of early intervention within 24 hours stratified by sex and CS type.

Unadjusted results. Figure 1A and 1B shows results for non-AMI-CS and AMI-CS, respectively.

Abbreviations: AMI-CS, acute myocardial infarction cardiogenic shock; PCI, percutaneous coronary intervention; CABG, coronary artery bypass grafting; MCS, mechanical support device; IABP, intra-aortic balloon pump; pLVAD, percutaneous left ventricular support device; ECMO, extracorporeal membrane oxygenation; RHC, right heart catheterization; LVAD, left ventricular assist device.

*p<0.001




Figure 2. Adjusted odds ratios of receiving early intervention within 24 hours of admission stratified by CS type.

All analyses involve multivariate logistic regression and are survey weight adjusted. Odds ratios reported are adjusted for year of NIS data, age group, race, household income quartile, insurance status, hospital type and teaching status as well as past medical history of diabetes mellitus, hypertension, dyslipidemia, tobacco use, obesity, chronic kidney disease, liver disease, peripheral vascular disease, coronary artery disease, chronic heart failure, valvular heart disease, stroke, prior PCI, and prior CABG.

Note: advanced heart failure therapies data not reported due to low counts preventing proper construction of logistic regression.

Abbreviations: AMI-CS, acute myocardial infarction cardiogenic shock; PCI, percutaneous coronary intervention; CABG, coronary artery bypass grafting; MCS, mechanical support device; IABP, intra-aortic balloon pump; pLVAD, percutaneous left ventricular support device; ECMO, extracorporeal membrane oxygenation; RHC, right heart catheterization.




Figure 3. Adjusted odds ratios of in-hospital mortality following early intervention within 24 hours of admission stratified by CS type.

All analyses involve multivariate logistic regression and are survey weight adjusted. Each regression is performed on a dataset filtered to only include CS patients who received a particular intervention within 24 hours. Odds ratios reported are adjusted for year of NIS data, age group, race, household income quartile, insurance status, hospital type and teaching status as well as past medical history of diabetes mellitus, hypertension, dyslipidemia, tobacco use, obesity, chronic kidney disease, liver disease, peripheral vascular disease, coronary artery disease, chronic heart failure, valvular heart disease, stroke, prior PCI, and prior CABG.

Note: advanced heart failure therapies data not reported due to low counts preventing proper construction of logistic regression.

Abbreviations: AMI-CS, acute myocardial infarction cardiogenic shock; PCI, percutaneous coronary intervention; CABG, coronary artery bypass grafting; MCS, mechanical support device; IABP, intra-aortic balloon pump; pLVAD, percutaneous left ventricular support device; ECMO, extracorporeal membrane oxygenation; RHC, right heart catheterization.

